Health Care • Biotechnology: Pharmaceutical Preparations
$86.39 ▲ +0.58
(+0.68%)
MKT CAP: $5.61B • VOL: 591.4K
52W L $63 52W H $130
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$73
MEDIAN
$97
MEAN
$98
HIGH
$117
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MIRM TAPE
MIRM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $104.53 | $99.35 | 2025-02-14 | $78.61 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $108.85 | $101.94 | 2025-02-06 | $81.21 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $98.48 | $95.03 | 2025-01-29 | $82.93 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $88.12 | — | 2025-01-17 | $84.66 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $76.02 | $82.07 | 2025-01-09 | $76.89 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $102.80 | $89.85 | 2024-12-18 | $75.16 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $83.80 | $87.25 | 2024-12-04 | $80.34 | -4.3% | 48% | C |